Association of Endogenous Tissue Plasminogen Activator (t-PA) with Clinical Characteristics of the Insulin Resistance Syndrome

[1]  P. Ridker.  Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events , 2005, Journal of Thrombosis and Thrombolysis.

[2]  M. Alessi,et al.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis , 1991, Diabetologia.

[3]  J. Després.  Insulin resistance and hyperglycemic associated risk factors: session summary. , 1999, Diabetes care.

[4]  J. Yudkin.  Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? , 1999, Diabetes Care.

[5]  M. Alessi,et al.  PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events , 1997, Thrombosis and Haemostasis.

[6]  K. Polonsky,et al.  Troglitazone Improves Defects in Insulin Action , Insulin Secretion , Ovarian Steroidogenesis , and Fibrinolysis in Women with Polycystic Ovary Syndrome * , 1997 .

[7]  J. Yudkin,et al.  Diminished Fibrinolysis in Diabetes Mellitus and its Implication for Diabetic Vascular Disease , 1997, Journal of cardiovascular risk.

[8]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[9]  C. Christiansen,et al.  Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[10]  I. Sartori.  Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .

[11]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[12]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[13]  G. Reaven.  Syndrome X: 6 years later. , 1994, Journal of internal medicine. Supplement.

[14]  B. Balkau,et al.  The epidemiology of coronary heart disease in glucose-intolerant and diabetic subjects. , 1994, Journal of internal medicine. Supplement.

[15]  S. Thompson,et al.  Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  P. Ridker,et al.  A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[17]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[18]  R R Wing,et al.  Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[19]  ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. , 1993, European heart journal.

[20]  B. Sobel,et al.  Direct Effects of Gemfibrozil on the Fibrinolytic System: Diminution of Synthesis of Plasminogen Activator Inhibitor Type 1 , 1992, Circulation.

[21]  J. Jansson,et al.  Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. , 1991, European heart journal.

[22]  U. Smith,et al.  Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease , 1990, Journal of internal medicine.

[23]  F. España,et al.  Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. , 1989, Thrombosis research.

[24]  R. Stenling,et al.  Reduction of Elevated Plasminogen Activator Inhibitor Levels During Modest Weight Loss , 1989 .

[25]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[26]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[27]  B. Winblad,et al.  Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. , 1986, Clinical chemistry.

[28]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.